Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients
A Prospective Study of Whole Genome Sequencing (ChromoSeq®) at Diagnosis for Pediatric, Adolescent, and Young Adult Acute Lymphoblastic Leukemia (ALL) Patients
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- Up to 30 Years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
- Time periods mentioned: 65 months
Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.
Show the study's own words
- "Sixty patients will undergo collections of bone marrow and/or peripheral blood for the ChromoSeq® assay at time of initial workup as part of standard of care, and the patients will then be followed for clinical outcomes for up to 65 months."
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
In plain language
This study tests whether ChromoSeq®, a test that reads all of a person’s DNA, can help classify acute lymphoblastic leukemia (ALL), a blood cancer, during the first medical tests. It is for children and young adults under age 30 who may have ALL or whose ALL may have returned. The study will test bone marrow and/or blood from 60 patients and track their health for up to 65 months.
This is a prospective data collection study evaluating the feasibility of using the ChromoSeq® assay for upfront classification in a real-time clinical setting of pediatric and young patients suspected of having ALL. Sixty patients will undergo collections of bone marrow and/or peripheral blood for the ChromoSeq® assay at time of initial workup as part of standard of care, and the patients will then be followed for clinical outcomes for up to 65 months.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Who can join
- Be under age 30 when joining the study.
- Receive care at St. Louis Children’s Hospital/Washington University School of Medicine.
- Be suspected of having B-cell or T-cell ALL, either for the first time or after it has returned.
- The patient and/or a parent or legal guardian must understand and sign a written form agreeing to join the study.
- Patients may also join a treatment study. This study does not recommend which treatment to use.
Who can't join
Simplified for readability. The official criteria below are what the study team uses.
Official eligibility criteria
Eligibility Criteria * Children and young adult patients (\< 30 years of age at time of study enrollment) treated at St. Louis Children's Hospital/Washington University School of Medicine. * Suspected diagnosis or suspected relapse of acute lymphoblastic leukemia (ALL), B- or T-cell. * Concurrent enrollment on a prospective therapeutic trial is allowed as this protocol makes no recommendations regarding treatment approach. * Ability to understand and willingness to sign an IRB approved written informed consent document. All patients and/or their parents or legal guardians must sign an IRB approved written informed consent document.
Study sites (1)
MO
- Washington University School of Medicine/St. Louis Children's Hospital · St Louis, MO 63110Margaret Ferris, MD, PhD · Study contact · 314-454-6018 · youngm@wustl.eduMargaret Ferris, MD, PhD · Principal investigatorFeng Gao, PhD · Sub-investigatorMore trials in St Louis